The NTI Development to Improve the Treatment of Pneumonia Caused by Coronavirus


PM&HM is preparing to market inhalers for the comprehensive treatment of a wide range of serious diseases, including pneumonia caused by human infection with coronavirus (COVID-19). PM&HM received investments from the RVC National Technology Initiative Project Support Fund.

The COVID-19 virus causes the development of the most severe form of the inflammatory process in lungs — bilateral interstitial confluent pneumonia. This disease is characterized by the attachment of a bacterial infection to viral pneumonia, which leads to the development of respiratory distress syndrome. Afterward, sepsis significantly increases the risk of death.

The development of the disease takes place against a background of spasm in the bronchi and the release of a large amount of sputum. As a result, the amount of oxygen in the lungs decreases, tissue starvation sets in, and patients are transferred to artificial lung ventilation. In such conditions, the effectiveness of the traditional delivery of medicines, both orally and through injection, is significantly reduced.

All existing inhalers supply aerosol to the respiratory tract regardless of the function of breathing and airway. Therefore 25–65% or more of the dose of the medicine settles in the upper respiratory tract or intubation tube without getting into the focus of inflammation. PM&HM inhalers are capable of generating aerosol, which increases the effectiveness of such therapy tenfold.

Oleg Abdiev, the founder of PM&HM
Firstly, our inhalers generate an aerosol that does not settle in the upper respiratory tract and reaches the lungs' affected parts. The aerosol itself is supplied just before the patient's breath. It is expected that drug delivery efficiency with this approach will increase significantly. Secondly, our inhalers can work with different types of medications that are used to treat pneumonia, including those caused by the COVID-19 virus — medicines that relieve bronchospasm, mucolytics for sputum discharge, and antibiotics for antibiotic therapy. In conditions where the patient's respiratory functions are extremely weakened, and the medicines must be delivered sequentially, a critical factor for the effectiveness of treatment is the determination of the time interval within which it is possible to introduce an antibiotic into the affected parts of the lungs. It is assumed that this time interval will be short enough. Therefore, it is the digital control of drug administration that will make it possible to track the time of administration, the sequence of use of medicines, and, most importantly, to control the dose that must be delivered to the lungs.

The cost of PM&HM inhalers will be from three thousand roubles. The device is currently undergoing tests for state registration. It is planned to equip state medical institutions with inhalers, including those under compulsory medical insurance. Testing of the proposed solutions is planned in pilot regions based on medical institutions.

Vladimir Alexandrovich Krasnov, Professor, Doctor of Medical Sciences
This technique is most relevant for acute respiratory distress syndrome when anti-inflammatory proteases and toxic oxygen metabolites are released in large quantities in response to inflammation in the lungs. This leads to damage to the endothelium of the capillaries and the epithelium of the alveoli. As a result, hypoxia occurs. Inhalation with this method makes it possible to increase the speed of exposure to medicines, thereby increasing the effectiveness of therapy.

The NTI Project Support Fund has invested 305 million roubles in the authorized capital of PM&HM in 2019. The project received support within the framework of the NTI roadmap Healthnet.


About the NTI

The National Technology Initiative is a long-term program to create new markets and provide conditions for Russia's technological leadership by 2035. The NTI focuses on those markets in which it is possible to develop industries of a new technical order that are significant in terms of ensuring national security and a high standard of living for citizens. Today, the NTI brings together thousands of people — technological entrepreneurs, representatives of leading universities and research centers, development institutes, authorities, expert and professional communities. As part of the NTI, eight Market Roadmaps of Aeronet, Autonet, Marinet, Neuronet, Healthnet, Energynet, Technet, and the Club's movement have been approved, and about 500 projects received sponsorship. The design office of the NTI is RVC.

Search by name:

Search by date:

Select date in calendar
Select date in calendar